REGENXBIO (RGNX) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed REGENXBIO (RGNX) over the past year, gaining 81.3% versus a loss of 33.8%. Over five years, SLN leads with a -56.4% price change compared with -77.5% for RGNX. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($626.8 million vs $530.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGNX | SLN |
|---|---|---|
| Share price | $8.04 | $10.09 |
| Market cap | $530.75M | $626.82M |
| 1-day change | -0.62% | +5.93% |
| YTD return | -43.82% | +56.58% |
| 1-year return | -33.80% | +81.33% |
| 5-year return | -77.50% | -56.37% |
| EPS (TTM) | $-3.78 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.19 | $17.58 |
| 52-week low | $5.46 | $4.19 |
| Distance from 52-week high | -50.34% | -42.62% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +193.28% | +227.22% |
| Average volume | 1.53M | 1.14M |
| Shares outstanding | 66.01M | 62.15M |
| Employees | 371 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed RGNX by 115.1 percentage points over the past year.
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
RGNX vs SLN FAQ
Which is bigger, REGENXBIO or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $626.82M compared with $530.75M for REGENXBIO (RGNX).
Which stock has performed better over the past year, RGNX or SLN?
SLN returned +81.33% over the past 12 months, compared with -33.80% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are REGENXBIO and Silence Therapeutics Plc American Depository Share in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO and Biotechnology: Pharmaceutical Preparations for Silence Therapeutics Plc American Depository Share.